Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
WCO | Ann: Banking Covenants Update | 01/10/24 | 0 | 44 | |||
|
|||||||
WCO | Ann: Results of WasteCo Group Limited Annual Shareholder Meeting | 12/09/24 | 0 | 95 | |||
|
|||||||
WCO | Ann: Annual General Meeting - Chairmans Speech and presentation | 12/09/24 | 0 | 81 | |||
|
|||||||
WCO | Ann: Banking Covenant Update | 11/09/24 | 0 | 91 | |||
|
|||||||
WCO | Ann: WCO appoints new Chief Operating Officer | 28/08/24 | 0 | 94 | |||
|
|||||||
WCO | Ann: AMENDED NOTICE OF 2024 ANNUAL SHAREHOLDERS' MEETING | 19/08/24 | 0 | 130 | |||
|
|||||||
WCO | Ann: NOTICE OF 2024 ANNUAL SHAREHOLDERS' MEETING | 19/08/24 | 0 | 108 | |||
|
|||||||
WCO | Ann: Carl Storm resigns from the Board | 16/08/24 | 0 | 86 | |||
|
See All Discussions